ArticleReports of biochemistry & molecular biology2025
Potential Anti-inflammatory Effects of Nanocurcumin via Modulation of MicroRNA-21 and MicroRNA-34a in Osteoarthritis Patients.
Article in Reports of biochemistry & molecular biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Osteoarthritis (OA) is the most common type of arthritis, characterized by inflammation that can affect the joint structures, leading to pain and disability, and is directly linked to ageing. As an epigenetic risk factor, microRNAs (miRNAs), small non-coding RNAs, can play a role in OA pathogenesis by regulating genes involved in processes such as inflammation, apoptosis, and autophagy. Due to the unique therapeutic potential of curcumin, isolated from Curcuma longa, particularly its anti inflammatory properties, the current study aimed to investigate the effect of the nanomicelle formulation of curcumin, named SinaCurcumin®, on the expression of miRNA-21 and miRNA-34a genes in OA patients. Methods: Thirty female patients with osteoarthritis were randomly assigned to two equal groups, who received nanocurcumin (n=15) and placebo (n=15) in a double-blind clinical trial for 3 months. The gene expression levels of miRNA-21 and miRNA-34a were evaluated using the SYBR® Green Real-Time PCR method. The association between the changes in expression of miRNA-21 and miRNA-34a and the changes in clinical and laboratory indexes in OA patients was analyzed using Spearman's rank correlation. Results: In the nanocurcumin group, the gene expression of miRNA-21 and miRNA-34a was significantly reduced, while no significant changes were observed in the placebo group. Also, there was a significant positive correlation between the downregulation of miRNA-21 and miRNA-34a and a decline in clinical and laboratory indexes (Visual Analog Scale and C-reactive protein) in patients receiving nanocurcumin. Conclusions: Curcumin may provide a promising therapeutic perspective for improving inflammation in OA through its modulatory effects on miRNA-21 and miRNA-34a.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.